

The Role of Partnerships in Accelerating CCR's Translational Research Progress



Robert H. Wiltrout
Director, CCR

Distinctive Qualities of CCR

- Critical mass of basic and clinical scientists solving complex scientific problems
- Can quickly redeploy resources to address:
 - (a) NCI mission goals
 - (b) Urgent public need
 - (c) New opportunities
- Access to NIH Clinical Center


Warren Grant Magnuson Clinical Center

Mark O. Hatfield Clinical Research Center


NIH Clinical Center



The Center for Cancer Research: A Comprehensive Translational Research Program



The Center for Cancer Research: A Comprehensive Translational Research Program



CCR's Mission Includes Establishing Partnerships

Including....but not limited to:

- CCR Lab/Branch Collaborations
- Trans-NCI Collaborations
- Trans-NIH Collaborations
- Intramural/Extramural Collaborations
- Partnerships with Industry
- Partnerships with Pharmaceutical Companies
- Partnerships with Other Federal Agencies
- National and International Consortia

...And of course, combinations of the above

Leveraging CCR Funds in Support of Intramural/Extramural Partnerships

- Cancer Imaging
- Ovarian Cancer Recurrence Trial
- Leukemia and Lymphoma Molecular Profiling Project
- HPV Vaccine
- Phase 0 Initiative
- Pediatric Preclinical Pharmacology Consortia
- Comparative Pathology Training Program
- Health Disparities
- SPOREs
- 3-D Tomography
- Glioma Molecular Diagnostics Initiative
- Comparative Oncology Program
- Energy Balance Initiative
- Molecular Epidemiology Consortia
- Familial Cancer Consortia
- Trans-NIH Angiogenesis Research Program
- Multiple Ongoing Clinical Trial Collaborations
- Bioinformatics
- IL-15

A Strong Basic Science Foundation Facilitates Multidisciplinary Translational Research Partnerships

- **Mary Carrington, PhD**
Host Immunogenetic Variation has Dramatic Consequences on HIV Disease
- CCR Lab/Branch, Trans-NCI, Intramural/Extramural -
- **Javed Khan, MD**
Microarrays and Artificial Neural Networks for Diagnosis, Prognosis and Selection of Therapeutic Targets & NanoBioSensor Initiative
- Intramural/Extramural, Federal Agencies, National/International Consortia -
- **David Wink, PhD**
“NO” Research with Potential for High Impact
- CCR Lab/Branch, Trans-NCI, Trans-NIH, Intramural/Extramural, Industry -
- **Steven Libutti, MD**
Highly Collaborative Angiogenesis Research Program
- CCR Lab/Branch, Trans-NCI, Trans-NIH, Intramural/Extramural, Industry -

National Cancer Institute

Center for Cancer Research



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health